First human tests begin for new malaria pill

NCT ID NCT06171113

Summary

This is the first study in humans to test the safety of a new oral drug called GSK4024484, which is being developed to treat falciparum malaria. The trial will enroll 156 healthy adult volunteers to see how their bodies handle single and multiple doses of the drug, and whether taking it with food makes a difference. The main goal is to understand the drug's safety profile and how it moves through the body before testing it in people with malaria.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA FALCIPARUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GSK Investigational Site

    RECRUITING

    Cambridge, CB2 0GG, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.